Ambitions to reach more patients with unmet needs have fueled some benevolent plans by bio/pharmaceutical companies ViiV Healthcare and Sandoz.
In recognition of the immense value of their HIV prevention treatment, ViiV Healthcare is entering into a patent license agreement with the United Nations (UN)-backed Medicines Patent Pool (MMP) to facilitate large-scale access to cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP) in low- and middle-income countries. These plans build on an existing relationship between the two organizations that has seen low-cost versions of other ViiV drugs become available in countries most in need of HIV treatment.
Deborah Waterhouse, Chief Executive Officer (CEO) of ViiV Healthcare, said: “We are excited about the potential role this long-acting injectable HIV prevention drug can play in helping to prevent HIV transmission and end HIV infection. epidemic by 2030. We look forward to working at MPP’s pace to execute the license in the coming months, building on the experience of our valued long-standing partnership.
Elsewhere, generic drugs and biosimilars company Sandoz has announced that it is sponsoring a global initiative called “Act4Biosimilars” with similar goals to expand access to advanced medicines and correct healthcare inequities around the world.
Led by a steering committee comprised of biosimilars experts, patient advocacy groups, healthcare professionals and industry leaders, Act4Biosmilars has defined 12 goals aimed at improving approval, accessibility, acceptability and affordability (called the 4As) – which represent the main barriers to wider adoption of biosimilars.
Biosimilars are successors to biological products whose patents have expired but which match their reference medicine in terms of quality, safety and efficacy. Used to treat and prevent many disabling and life-threatening diseases such as cancer and diabetes, the initiative aims to increase global uptake of biosimilar medicines by at least 30% in at least 30 countries by 2030.
Emphasizing the need to pilot this initiative, Professor Emeritus Tore K Kvien, Former Head of Department of Rheumatology, Diakonhjemmet Hospital, Norway, explained: “While countries like Norway are leading the way in the adoption of biosimilars and have To achieve significant health care savings by increasing availability of biosimilars, other countries are still making progress and aspire to reach their full potential.
“Misinformation about the safety, efficacy and science of biosimilars continues to confuse and hinder adoption. With the Act4Biosimilars Action Plan, we will prioritize the steps needed to help better educate, inform and create actions in all countries and regions.
Related diseases and conditions